Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 27Unknown 3Terminated 3Recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Biphenotypic, Acute 14Recurrence 13Myelodysplastic Syndromes 13Leukemia 12Burkitt Lymphoma 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 6Lymphoma, Mantle-Cell 5Neoplasm, Residual 4Myeloproliferative Disorders 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma, Myeloid 3Lymphoma, T-Cell 3Lymphoma 3Blast Crisis 3Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid 2Down Syndrome 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Targeted Therapy 1Pyloric Stenosis, Hypertrophic 1Neurofibromatosis 1 1Neoplasms by Histologic Type 1

Interventions

Cyclophosphamide 8fludarabine phosphate 7fludarabine 5Busulfan 5Mycophenolic Acid 4Melphalan 4Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Filgrastim 3Azacitidine 3venetoclax 2thymoglobulin 2Tacrolimus 2Rituximab 2Injections 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Cytarabine 2Cyclosporins 2Clofarabine 2Bone Marrow Transplantation 2Antilymphocyte Serum 2sulforaphane 1ruxolitinib 1pegylated granulocyte colony-stimulating factor 1monalizumab 1ivosidenib 1enasidenib 1cedazuridine 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Anemia, Refractory, with Excess of Blasts × Cytarabine × Clear all
NCT07588360 2026-05-14

Haplo-Cord HSCT for AML/MDS

Fujian Medical University Union Hospital

Phase NA Recruiting
180 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡